| ²é¿´: 247 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
ronghui05ͳæ (СÓÐÃûÆø)
|
[½»Á÷]
ҽѧÀ࣬лл£¡
|
||
| Gene therapy and viro therapy are among the approaches currently used to treat malignant tumors. Gene therapy and viro therapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area. |
» ²ÂÄãϲ»¶
Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
297Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
288Çóµ÷¼Á Ò»Ö¾Ô¸¹þ¹¤´ó ²ÄÁÏÓ뻯¹¤
ÒѾÓÐ12È˻ظ´
085600£¬320·ÖÇóµ÷¼Á
ÒѾÓÐ10È˻ظ´
085600²ÄÁÏÓ뻯¹¤µ÷¼Á
ÒѾÓÐ27È˻ظ´
Çóµ÷¼Á£¬Ò»Ö¾Ô¸Ö£ÖÝ´óѧ²ÄÁÏÓ뻯¹¤×¨Ë¶£¬Ó¢¶þÊý¶þ342·Ö£¬ÇóÀÏʦÊÕÁô
ÒѾÓÐ19È˻ظ´
292Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
270»¯¹¤Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
²ÄÁÏ295
ÒѾÓÐ14È˻ظ´
266Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
Íô¶«Éýwds
гæ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 2637.1
- ºì»¨: 1
- Ìû×Ó: 145
- ÔÚÏß: 25.5Сʱ
- ³æºÅ: 910894
- ×¢²á: 2009-11-23
- ÐÔ±ð: GG
- רҵ: ΢ÉúÎïÉúÀíÓëÉúÎﻯѧ
¡ï ¡ï ¡ï
ronghui05(½ð±Ò+3,VIP+0):лл£¡ 1-16 09:49
ronghui05(½ð±Ò+3,VIP+0):лл£¡ 1-16 09:49
|
Gene therapy and viro therapy are among the approaches currently used to treat malignant tumors. Gene therapy and viro therapy use a specific therapeutic gene that causes death in cancer cells. In early attempts at gene therapy, therapeutic genes were driven by ubiquitous promoters such as the CMV promoter, which induce non-specific toxicity to normal cells and tissues in addition to the cancer cells. Recently, novel cancer- and/or tissue-specific promoter systems have been developed to target cancer cells but not normal cells including stem cells. In this review, we describe cancer and/or tissue-specific gene therapy systems for the treatment of cancer. In particular, we will discuss three systems for gene therapy and virotherapy: i) tissue-specific promoter systems, ii) cancer-specific promoter systems, and iii) oncolytic virotherapy. We will also discuss the major challenges of cancer-targeting vector systems and future directions in this area. »ùÒòÖÎÁÆ»òÕß²¡¶¾ÖÎÁÆÊÇĿǰ¶Ô¸¶¶ñÐÔÖ×ÁöµÄ·½·¨¡£»ùÒòÖÎÁƺͲ¡¶¾ÖÎÁÆÊ¹ÓÃÒ»¸öÄÜÖÂËÀ°©Ï¸°ûµÄÌØÒìÐÔÖÎÁÆ»ùÒò¡£ÔÚÔçÆÚµÄ»ùÒòÖÎÁÆÊÔÑéÖУ¬ÖÎÁÆ»ùÒòÊÇÓÉÒ»¸öͨÓÃµÄÆô¶¯×ÓÇý¶¯µÄ£¬±ÈÈçCMVÆô¶¯×Ó£¬Ëü³ýÁË¿ÉɱËÀ°©Ï¸°ûÍ⣬»¹¿ÉÓÕµ¼²úÉúÕë¶ÔÕý³£Ï¸°ûºÍÆ÷¹ÙµÄ¶¾ÐÔ¡£×î½ü£¬Ðµİ©Ï¸°û»òÆ÷¹ÙÌØÒìÐÔÆô¶¯×ÓϵͳÒѾ¿ª·¢³öÀ´£¬ÆäÖ±Ö¸°©Ï¸°û£¬È´²»Ó°ÏìÕý³£Ï¸°ûºÍ¸Éϸ°û¡£ÔÚÏÂÎÄÖУ¬ÎÒÃǽ«»áÊöÓÃÓÚ°©Ö¢ÖÎÁư©Ï¸°û»ò×éÖ¯ÌØÒìÐÔÆô¶¯×Óϵͳ¡£ÎÒÃÇ»áרÃÅÌÖÂÛÈý¸ö»ùÒò»ò²¡¶¾ÖÎÁÆÏµÍ³£º1¡¢Æ÷¹ÙÌØÒìÐÔÆô¶¯×Óϵͳ£»2¡¢°©Ï¸°ûÌØÒìÐÔÆô¶¯×Óϵͳ£»3¡¢ÈÜÁö²¡¶¾ÖÎÁÆ¡£ÎÒÃÇÒ²»áÌÖÂÛÄ¿µÄ°©Ï¸°ûÔØÌåϵͳµÄÖ÷ÒªÌôÕ½¼°ÕâÒ»ÁìÓòµÄδÀ´·½Ïò |
2Â¥2010-01-15 16:21:47
yjhorn
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 1725.8
- Ìû×Ó: 629
- ÔÚÏß: 18.3Сʱ
- ³æºÅ: 33078
- ×¢²á: 2003-12-28
- ÐÔ±ð: GG
- רҵ: ½ðÈÚѧ
¡ï ¡ï ¡ï
ronghui05(½ð±Ò+3,VIP+0):лл£¡ 1-16 09:49
ronghui05(½ð±Ò+3,VIP+0):лл£¡ 1-16 09:49
|
Å×שÒýÓñ£º »ùÒòÖÎÁƺͲ¡¶¾ÖÎÁÆÊÇĿǰÖÎÁƶñÐÔÖ×Áö·½·¨ÖÐµÄÆäÖÐÁ½ÖÖ¡£»ùÒòÖÎÁƺͲ¡¶¾ÖÎÁÆÊÇʹÓÃÒ»¸öÌØÒìÐÔÖÎÁÆÐÍ»ùÒòÀ´É±ËÀ°©Ï¸°û¡£ÔÚ»ùÒòÖÎÁÆÊ¹ÓõÄÔçÆÚ½×¶Î£¬Ò»Ð©ÖÎÁÆÐÍ»ùÒòÊÇÓÉÒ»¸öͨÓÃµÄÆô¶¯×ÓÇý¶¯µÄ£¬±ÈÈçCMVÆô¶¯×Ó£¬ÕâÑù¿ÉÓÕ·¢Õý³£Ï¸°ûºÍ×éÖ¯ÒÔ¼°°©Ï¸°ûµÄ·ÇÌØÒìÐÔ¶¾ÐÔ¡£½üÀ´£¬£¨¿ÆÑ§¼Ò£©ÒÑ¿ª·¢³öÁËÐµİ©Ï¸°û»ò×éÖ¯ÌØÒìÐÔÆô¶¯×Óϵͳ£¬Æä°Ð±êÊǰ©Ï¸°û£¬µ«²¢²»Ó°ÏìÕý³£Ï¸°ûºÍ¸Éϸ°û¡£±¾ÎÄÎÒÃǽ«½éÉÜÓÃÓÚÖÎÁư©Ö¢µÄ°©Ö¢»ò×éÖ¯ÌØÒìÐÔÆô¶¯×Óϵͳ£¬ÓÈÆäÊÇÏÂÁÐÈý¸ö»ùÒò»ò²¡¶¾ÖÎÁÆÏµÍ³£º1¡¢×éÖ¯ÌØÒìÐÔÆô¶¯×Óϵͳ£»2¡¢°©Ö¢ÌØÒìÐÔÆô¶¯×Óϵͳ£»3¡¢ÈÜÁö²¡¶¾ÖÎÁÆ¡££¨Í¬Ê±£¬£©ÎÒÃÇÒ²»áÌÖÂÛ°©Ö¢°ÐÏòÔØÌåϵͳ£¨ÃæÁٵģ©Ö÷ÒªÌôÕ½¼°¸ÃÁìÓòδÀ´µÄ£¨·¢Õ¹£©·½Ïò¡£ |

3Â¥2010-01-15 20:10:32














»Ø¸´´ËÂ¥